Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies Journal Article
| Authors: | Naidoo, J.; Page, D. B.; Li, B. T.; Connell, L. C.; Schindler, K.; Lacouture, M. E.; Postow, M. A.; Wolchok, J. D. |
| Article Title: | Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies |
| Abstract: | Immune checkpoint antibodies that augment the programmed cell death protein 1 (PD-1)/PD-L1 pathway have demonstrated antitumor activity across multiple malignancies, and gained recent regulatory approval as single-agent therapy for the treatment of metastatic malignant melanoma and nonsmall-cell lung cancer. Knowledge of toxicities associated with PD-1/PD-L1 blockade, as well as effective management algorithms for these toxicities, is pivotal in order to optimize clinical efficacy and safety. In this article, we review selected published and presented clinical studies investigating singleagent anti-PD-1/PD-L1 therapy and trials of combination approaches with other standard anticancer therapies, in multiple tumor types. We summarize the key adverse events reported in these studies and their management algorithms. © 2015 The Author. |
| Keywords: | unclassified drug; fatigue; neutropenia; bevacizumab; fluorouracil; sunitinib; cancer combination chemotherapy; diarrhea; side effect; skin toxicity; solid tumor; cancer radiotherapy; rituximab; ipilimumab; ticilimumab; cancer immunotherapy; edema; melanoma; metastasis; antineoplastic metal complex; liver toxicity; nephrotoxicity; anemia; leukopenia; nausea; thrombocytopenia; vomiting; myalgia; kidney carcinoma; hodgkin disease; arthralgia; asthenia; chill; colorectal carcinoma; dyspnea; fever; lymphocytopenia; pneumonia; pruritus; rash; alanine aminotransferase; aspartate aminotransferase; acute kidney failure; hypoalbuminemia; maculopapular rash; hematologic malignancy; myelodysplastic syndrome; folinic acid; glioblastoma; pancreatitis; lymphoma; gefitinib; antiangiogenic therapy; pazopanib; peripheral edema; colitis; flu like syndrome; hyperthyroidism; hypothyroidism; toxicity; oxaliplatin; myasthenia gravis; autoimmune disease; insulin dependent diabetes mellitus; alopecia; neurologic disease; transitional cell carcinoma; sarcoidosis; follicular lymphoma; cholecystitis; antibody; endocrine disease; eye toxicity; respiratory tract infection; amylase; pancreas disease; triacylglycerol lipase; phosphorus; castration resistant prostate cancer; uveitis; non small cell lung cancer; adrenal insufficiency; molecularly targeted therapy; adverse event; decreased appetite; hypophysitis; autoimmune hepatitis; hypertransaminasemia; heart ejection fraction; thyroiditis; diabetic ketoacidosis; nephritis; folliculitis; myocarditis; polymyositis; dabrafenib; trametinib; nivolumab; infusion related reaction; bms 936559; pidilizumab; human; priority journal; article; anti-pd-1; anti-pd-l1; pembrolizumab; durvalumab; osimertinib; immune checkpoint antibody; atezolizumab; bms 39886; programmed cell death protein 1 immune checkpoint antibody; programmed death 1 ligand 1 immune checkpoint antibody; autoimmune nephritis; endocrine toxicity; pancreatic toxicity |
| Journal Title: | Annals of Oncology |
| Volume: | 26 |
| Issue: | 12 |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2015-12-01 |
| Start Page: | 2375 |
| End Page: | 2391 |
| Language: | English |
| DOI: | 10.1093/annonc/mdv383 |
| PROVIDER: | scopus |
| PUBMED: | 26371282 |
| PMCID: | PMC6267867 |
| DOI/URL: | |
| Notes: | Article -- 1 -- Export Date: 7 January 2016 -- 2375 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work